For a study, researchers provided a brief overview of the events involved in honeybee allergy and concisely updated the reader on progress toward knowledge of honeybee venom (HBV), stridden in resolving diagnostic challenges, and advanced in improving the safety and efficacy of HBV immunotherapy. Honeybee allergy was well understood to be distinct in terms of venom allergen and protein composition, diagnostic problems, and immunotherapy safety and effectiveness. Many novel allergies associated with honeybees had been identified. Advances in testing, assessment, and extract modification technologies, many of which use recombinant technology, had resulted in a better capacity to assist with honeybee allergy diagnosis, as well as an increase in immunotherapy safety and efficacy evaluation.

Specific advancements had recently been achieved in an effort to alleviate several honey bee allergy issues. Some newly identified honey bee allergens appeared to be significant factors to honey bee allergy. In the context of double-positivity, cross-reacting carbohydrate determinants and other cross-reacting components in HBV had made honey bee allergy diagnosis difficult. In the very near future, recombinant technology, including component-resolved diagnostics, and other emerging testing procedures, should assist explain double-positivity. Purified HBV, as well as perhaps depot formulations for immunotherapy, appeared to improve tolerability. Recombinant techniques aided in determining the safety and efficacy of immunotherapy.